Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044163005> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W2044163005 endingPage "3639" @default.
- W2044163005 startingPage "3633" @default.
- W2044163005 abstract "Background. In vitro studies have demonstrated that a brief exposure of peripherally collected mononuclear cells to high-dose human recombinant interleukin-2 (rIL-2) will generate a population of pulsed lymphokine-activated killer (LAK) cells. These cells have similar cytotoxicity against natural killer cells and resistant and sensitive target cells as compared with the standard LAK cells incubated for 3–7 days with rIL-2. Therefore, the authors conducted a pilot study to investigate the activity of pulsed LAK cells in patients with advanced cancer. Methods. Nineteen patients were enrolled in a pilot study, and pulsed LAK cell treatment was administered two times per week for 4 weeks, followed by similar cycles if patients remained free of disease progression and unacceptable toxic effects. Results. Toxic effects consisted mainly of fever, chills, nausea, and dizziness but were self-limiting and mild. Most cycles were administered on an outpatient basis. There were six partial responses (31%), occurring in two of three patients with renal cell carcinoma, two of four with hepatocellular carcinoma, one of seven with non-small cell lung carcinoma, and one of one with ovarian carcinoma. Two minimal responses were seen in one case each of melanoma and carcinoma of colon. Nine other patients had disease stabilization for 16 weeks, and two additional patients had disease progression. Pheno-typing of peripheral mononuclear cells showed increases in CD56 and CD25 populations with no in vivo rIL-2 being administered after treatment with pulsed LAK cells. Conclusions. The relative ease in generating pulsed LAK cells and the associated mild toxic effects enable prolonged stimulation of the effector cells of the patients against sensitive tumor targets, with a response rate comparable to those of high-dose rIL-2 and LAK cell treatment. Therefore, it may be a theoretically ideal adjuvant for patients with renal cell carcinoma, melanoma, and hepatoma and other applicable patients after bone marrow transplantation. The initial high response rate in patients with late-stage renal cell carcinoma and hepatocellular carcinoma indicates the need for additional confirmation." @default.
- W2044163005 created "2016-06-24" @default.
- W2044163005 creator A5007432989 @default.
- W2044163005 creator A5009454950 @default.
- W2044163005 creator A5031927932 @default.
- W2044163005 creator A5072691128 @default.
- W2044163005 creator A5081626963 @default.
- W2044163005 date "1993-06-01" @default.
- W2044163005 modified "2023-09-26" @default.
- W2044163005 title "Short-duration in vitro interleukin-2–activated mononuclear cells for advanced cancer. A hong kong biotherapy pilot study trial" @default.
- W2044163005 cites W1985981664 @default.
- W2044163005 cites W2036275492 @default.
- W2044163005 cites W2044674177 @default.
- W2044163005 cites W2049822454 @default.
- W2044163005 cites W2081067850 @default.
- W2044163005 cites W2133818380 @default.
- W2044163005 cites W2138463196 @default.
- W2044163005 cites W2153784269 @default.
- W2044163005 cites W2242340339 @default.
- W2044163005 doi "https://doi.org/10.1002/1097-0142(19930601)71:11<3633::aid-cncr2820711127>3.0.co;2-c" @default.
- W2044163005 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8387882" @default.
- W2044163005 hasPublicationYear "1993" @default.
- W2044163005 type Work @default.
- W2044163005 sameAs 2044163005 @default.
- W2044163005 citedByCount "5" @default.
- W2044163005 crossrefType "journal-article" @default.
- W2044163005 hasAuthorship W2044163005A5007432989 @default.
- W2044163005 hasAuthorship W2044163005A5009454950 @default.
- W2044163005 hasAuthorship W2044163005A5031927932 @default.
- W2044163005 hasAuthorship W2044163005A5072691128 @default.
- W2044163005 hasAuthorship W2044163005A5081626963 @default.
- W2044163005 hasBestOaLocation W20441630051 @default.
- W2044163005 hasConcept C121608353 @default.
- W2044163005 hasConcept C126322002 @default.
- W2044163005 hasConcept C129374314 @default.
- W2044163005 hasConcept C137061746 @default.
- W2044163005 hasConcept C143998085 @default.
- W2044163005 hasConcept C202751555 @default.
- W2044163005 hasConcept C203014093 @default.
- W2044163005 hasConcept C2776090121 @default.
- W2044163005 hasConcept C2777371288 @default.
- W2044163005 hasConcept C2777701055 @default.
- W2044163005 hasConcept C2778594517 @default.
- W2044163005 hasConcept C2778690821 @default.
- W2044163005 hasConcept C28651165 @default.
- W2044163005 hasConcept C2908647359 @default.
- W2044163005 hasConcept C55493867 @default.
- W2044163005 hasConcept C71924100 @default.
- W2044163005 hasConcept C86803240 @default.
- W2044163005 hasConcept C8891405 @default.
- W2044163005 hasConcept C90924648 @default.
- W2044163005 hasConcept C99454951 @default.
- W2044163005 hasConceptScore W2044163005C121608353 @default.
- W2044163005 hasConceptScore W2044163005C126322002 @default.
- W2044163005 hasConceptScore W2044163005C129374314 @default.
- W2044163005 hasConceptScore W2044163005C137061746 @default.
- W2044163005 hasConceptScore W2044163005C143998085 @default.
- W2044163005 hasConceptScore W2044163005C202751555 @default.
- W2044163005 hasConceptScore W2044163005C203014093 @default.
- W2044163005 hasConceptScore W2044163005C2776090121 @default.
- W2044163005 hasConceptScore W2044163005C2777371288 @default.
- W2044163005 hasConceptScore W2044163005C2777701055 @default.
- W2044163005 hasConceptScore W2044163005C2778594517 @default.
- W2044163005 hasConceptScore W2044163005C2778690821 @default.
- W2044163005 hasConceptScore W2044163005C28651165 @default.
- W2044163005 hasConceptScore W2044163005C2908647359 @default.
- W2044163005 hasConceptScore W2044163005C55493867 @default.
- W2044163005 hasConceptScore W2044163005C71924100 @default.
- W2044163005 hasConceptScore W2044163005C86803240 @default.
- W2044163005 hasConceptScore W2044163005C8891405 @default.
- W2044163005 hasConceptScore W2044163005C90924648 @default.
- W2044163005 hasConceptScore W2044163005C99454951 @default.
- W2044163005 hasIssue "11" @default.
- W2044163005 hasLocation W20441630051 @default.
- W2044163005 hasLocation W20441630052 @default.
- W2044163005 hasOpenAccess W2044163005 @default.
- W2044163005 hasPrimaryLocation W20441630051 @default.
- W2044163005 hasRelatedWork W1608758521 @default.
- W2044163005 hasRelatedWork W17427955 @default.
- W2044163005 hasRelatedWork W2044163005 @default.
- W2044163005 hasRelatedWork W2091494965 @default.
- W2044163005 hasRelatedWork W2133759650 @default.
- W2044163005 hasRelatedWork W2134265617 @default.
- W2044163005 hasRelatedWork W2145472332 @default.
- W2044163005 hasRelatedWork W2416219730 @default.
- W2044163005 hasRelatedWork W4249205621 @default.
- W2044163005 hasRelatedWork W18987839 @default.
- W2044163005 hasVolume "71" @default.
- W2044163005 isParatext "false" @default.
- W2044163005 isRetracted "false" @default.
- W2044163005 magId "2044163005" @default.
- W2044163005 workType "article" @default.